


# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## 2022 Best Pharmaceuticals for Children Act (BPCA) Stakeholders Meeting MEETING EVALUATION


OMB#: 0925-0648 Exp Date: 6/2024

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

Thank you for attending the 2022 BPCA Stakeholders Meeting! we welcome your feedback so we can improve future meetings. Please click Next to begin the survey.

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute of Child Health and Human Development



## 2022 Best Pharmaceuticals for Children Act (BPCA) Stakeholders Meeting MEETING EVALUATION

### MEETING CONTENT

1. On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the session  
**FDA Reflections: Legislations Work, What is Still Needed?**

Poor

Excellent

★ ★ ★ ★ ★

Other (please specify)

2. On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the session  
**NIH BPCA Reflections: In the Air and On the Ground in the Pediatric Drug Development Space.**

Poor

Excellent

★ ★ ★ ★ ★

Other (please specify)

3. On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the session  
**Off-Label, but On-Evidence? From Problem to Solution.**

Poor

Excellent

★ ★ ★ ★ ★

Other (please specify)

4. On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the **Status of Pediatric Drug Development Discussion.**

Poor Excellent



Other (please specify)

5. On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the session **Updates from the Pediatric Trials Network.**

Poor Excellent



Other (please specify)

6. On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the **Future of Pediatric Drug Development Discussion.**


Poor Excellent



Other (please specify)

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## 2022 Best Pharmaceuticals for Children Act (BPCA) Stakeholders Meeting MEETING EVALUATION

### LOGISTICAL FEEDBACK

7. Please rate the overall meeting logistics (e.g., virtual meeting format, logistical support, registration process, etc.)

Poor


Excellent

★	★	★	★	★
---	---	---	---	---

Other (please specify)

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## 2022 Best Pharmaceuticals for Children Act (BPCA) Stakeholders Meeting MEETING EVALUATION

### GENERAL FEEDBACK

8. On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” what is your overall rating of the meeting?

Poor

Excellent

★ ★ ★ ★ ★

9. How can we improve the next BPCA Stakeholders Meeting?

10. Please provide any additional comments here.

11. Name and Email Address (optional)

Please provide your email address if you would like a response to your comments.

Name

Email Address